Antiplatelet therapy for the prevention of atherosclerosis in chronic kidney disease (ALTAS-CKD) patients: study protocol for a randomized clinical trial.
Jiachuan XiongTing HeZhikai YuKe YangFeng ChenJingbo ChengYu ShiYinghui HuangYu QiaoHaiyang LiYunzhu ShenJinghong ZhaoPublished in: Trials (2021)
The ALTAS-CKD study is a multicenter, prospective, randomized, double-blind, placebo-controlled trial of 554 adult patients with stage 3-5 non-dialysis-dependent CKD recruited from 10 territory medical centers in China. A secured web-based computer randomization system will be used to administer aspirin 100 mg once daily or a matching inactive placebo for 36 months. The primary endpoint will be the occurrence of atherosclerosis, as measured by carotid ultrasonography. The secondary endpoints will be combined cardiovascular events, all-cause mortality, and 50% decrease in the estimated glomerular filtration rate. TRIAL REGISTRATION {2A}: Current controlled trials number: ChiCTR1900021393 . Registered on 18 February 2019.
Keyphrases
- double blind
- chronic kidney disease
- end stage renal disease
- cardiovascular events
- placebo controlled
- phase iii
- antiplatelet therapy
- clinical trial
- phase ii
- cardiovascular disease
- study protocol
- acute coronary syndrome
- coronary artery disease
- peritoneal dialysis
- percutaneous coronary intervention
- magnetic resonance imaging
- ejection fraction
- healthcare
- open label
- newly diagnosed
- low dose
- risk assessment
- prognostic factors
- deep learning
- cross sectional
- magnetic resonance